Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial

A. Eisen, CP. Cannon, E. Braunwald, DL. Steen, J. Zhou, EL. Goodrich, K. Im, AJ. Dalby, J. Spinar, S. Daga, MA. Lukas, ML. O'Donoghue,

. 2017 ; 6 (1) : . [pub] 20170111

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010858

BACKGROUND: High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. METHODS AND RESULTS: The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as ≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n=12 446), 11 850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14 days), but only 5212 (41.9%) were on a high-potency statin. Selected patient factors associated with nonuse of high-potency statins included age ≥75 years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), renal dysfunction (odds ratio 1.17, 95% CI 1.03-1.32), and heart failure during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3 months after baseline, only 49% of patients had low-density lipoprotein cholesterol <70 mg/dL. Among the 5490 patients (59%) who were not on a high-potency statin at 3 months, lower low-density lipoprotein cholesterol was a predictor of nonuse of a high-potency statin after a median of 2.3 years (odds ratio 1.15 for 10 mg/dL decrease, 95% CI 1.11-1.19). CONCLUSION: Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with high-potency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01000727.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010858
003      
CZ-PrNML
005      
20180416135620.0
007      
ta
008      
180404s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1161/JAHA.116.004332 $2 doi
035    __
$a (PubMed)28077384
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Eisen, Alon $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
245    10
$a Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial / $c A. Eisen, CP. Cannon, E. Braunwald, DL. Steen, J. Zhou, EL. Goodrich, K. Im, AJ. Dalby, J. Spinar, S. Daga, MA. Lukas, ML. O'Donoghue,
520    9_
$a BACKGROUND: High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. METHODS AND RESULTS: The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as ≥40 mg atorvastatin, ≥20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n=12 446), 11 850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14 days), but only 5212 (41.9%) were on a high-potency statin. Selected patient factors associated with nonuse of high-potency statins included age ≥75 years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), renal dysfunction (odds ratio 1.17, 95% CI 1.03-1.32), and heart failure during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3 months after baseline, only 49% of patients had low-density lipoprotein cholesterol <70 mg/dL. Among the 5490 patients (59%) who were not on a high-potency statin at 3 months, lower low-density lipoprotein cholesterol was a predictor of nonuse of a high-potency statin after a median of 2.3 years (odds ratio 1.15 for 10 mg/dL decrease, 95% CI 1.11-1.19). CONCLUSION: Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with high-potency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01000727.
650    _2
$a akutní koronární syndrom $x farmakoterapie $7 D054058
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a nestabilní angina pectoris $x farmakoterapie $7 D000789
650    _2
$a atorvastatin $x aplikace a dávkování $7 D000069059
650    _2
$a benzaldehydy $x terapeutické užití $7 D001547
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční selhání $x epidemiologie $7 D006333
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x aplikace a dávkování $7 D019161
650    _2
$a logistické modely $7 D016015
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu $x farmakoterapie $7 D009203
650    _2
$a odds ratio $7 D016017
650    _2
$a oximy $x terapeutické užití $7 D010091
650    _2
$a inhibitory fosfolipasy A2 $x terapeutické užití $7 D064801
650    12
$a lékařská praxe - způsoby provádění $7 D010818
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a renální insuficience $x epidemiologie $7 D051437
650    _2
$a rosuvastatin kalcium $x aplikace a dávkování $7 D000068718
650    _2
$a sekundární prevence $7 D055502
650    _2
$a sexuální faktory $7 D012737
650    _2
$a simvastatin $x aplikace a dávkování $7 D019821
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cannon, Christopher P $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
700    1_
$a Braunwald, Eugene $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
700    1_
$a Steen, Dylan L $u University of Cincinnati, OH.
700    1_
$a Zhou, Jing $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
700    1_
$a Goodrich, Erica L $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
700    1_
$a Im, KyungAh $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
700    1_
$a Dalby, Anthony J $u Milpark Hospital, Johannesburg, South Africa.
700    1_
$a Spinar, Jindrich $u University Hospital Brno, Brno, Czech Republic.
700    1_
$a Daga, Shruti $u GlaxoSmithKline, Philadelphia, PA.
700    1_
$a Lukas, Mary Ann $u GlaxoSmithKline, Philadelphia, PA.
700    1_
$a O'Donoghue, Michelle L $u Cardiovascular Division, Brigham and Women's Hospital, Boston, MA modonoghue@partners.org.
773    0_
$w MED00188127 $t Journal of the American Heart Association $x 2047-9980 $g Roč. 6, č. 1 (2017)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28077384 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180416135717 $b ABA008
999    __
$a ok $b bmc $g 1288343 $s 1007670
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 6 $c 1 $e 20170111 $i 2047-9980 $m Journal of the American Heart Association $n J Am Heart Assoc $x MED00188127
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace